Related Experiment Video

Updated: Apr 2, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.9K

[Role of Receptor Tyrosine Kinase AXL in Cancer Targeted Therapy Drug Resistance]

Sutong Zhan1, Peilin Chen1, Tangfeng Lv1

  • 1Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210000, China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|March 31, 2026
PubMed

Insights

Receptor tyrosine kinase AXL promotes cancer drug resistance. Inhibiting AXL, especially in combination therapies, offers a promising strategy to overcome resistance and improve patient outcomes in targeted cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Drug resistance remains a significant challenge in targeted cancer therapy.
  • Abnormal expression of receptor tyrosine kinase AXL is linked to targeted therapy resistance and poor clinical outcomes.
  • AXL contributes to resistance through mechanisms like altered cell phenotypes, DNA damage response modulation, bypass signaling, and interactions with other receptor tyrosine kinases.

Purpose of the Study:

  • To review the role of AXL in mediating resistance to targeted cancer therapies.
  • To summarize current AXL-targeted treatment strategies and their efficacy.
  • To explore the clinical potential of combination therapies involving AXL inhibition.

Main Methods:

  • Review of preclinical and clinical studies on AXL's role in drug resistance.
  • Analysis of AXL-targeted treatment strategies and combinatorial approaches.
  • Discussion of future directions in AXL-targeted therapy and precision oncology.

Main Results:

  • AXL plays a critical role in various resistance mechanisms against targeted therapies.
  • Combined inhibition of AXL with other targets demonstrates enhanced efficacy in preclinical and clinical settings.
  • Combinatorial approaches involving AXL inhibition show potential for improving outcomes in drug-resistant cancers.

Conclusions:

  • AXL is a key mediator of targeted therapy resistance in cancer.
  • AXL-targeted therapies, particularly in combination, represent a promising strategy to overcome drug resistance.
  • Further research into combinatorial approaches involving AXL inhibition is crucial for advancing precision oncology.
Keywords:
AXLCancerDrug resistanceTargeted therapy

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K